Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell
investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in
the previous 18-36 hours.
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Other
Enrollment Eligibility
Primary Inclusion Criteria:
- Male or female subjects ≥18 years of age
- Clinical diagnosis of ischemic stroke involving cerebral cortex
- Occurrence of a moderate to moderately severe stroke with a persistent neurologic
deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4
points during the initial screening period
- A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke
Primary Exclusion Criteria:
- Presence of a lacunar or a brainstem infarct
- Comatose state
- Brain hemorrhage
- Major neurological event such as stroke or clinically significant head trauma within 6
months of enrollment into the study